Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)
Supporting research to improve precision medicine for pregnant and pediatric populations, focusing on drug safety and efficacy, and development of novel therapeutics.
Funder: National Institutes of Health
Due Dates: February 16, 2025 | June 16, 2025 | October 16, 2025 | February 16, 2026 | July 6, 2026
Funding Amounts: Up to $275,000 in direct costs over 2 years; no more than $200,000 in a single year.
Summary: Supports translational and clinical research to advance precision medicine and therapeutics for pregnant/lactating women, fetuses, neonates, and children, including those with disabilities.
Key Information: Clinical trial optional; broad eligibility including foreign organizations; strict NIH application compliance required.
Description
This funding opportunity supports translational and clinical research aimed at improving precision medicine and therapeutics in maternal and pediatric populations. Projects should focus on the development of novel tools, models, technologies, or therapeutics that directly impact clinical care or health outcomes for pregnant women, lactating women, fetuses, neonates, and children—including those with physical or intellectual disabilities. Research may also enhance understanding of drug action mechanisms, pediatric ontogeny, and the unique physiological changes during pregnancy and lactation. The overarching goal is to enable safer and more effective medications and dosing strategies for these populations, addressing significant gaps in current pharmacological knowledge and practice.
